keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous erythropoietin

keyword
https://www.readbyqxmd.com/read/28469772/epo-cyclosporine-combination-therapy-reduced-brain-infarct-area-in-rat-after-acute-ischemic-stroke-role-of-innate-immune-inflammatory-response-micro-rnas-and-mapk-family-signaling-pathway
#1
Chun-Man Yuen, Kuo-Ho Yeh, Christopher Glenn Wallace, Kuan-Hung Chen, Hung-Sheng Lin, Pei-Hsun Sung, Han-Tan Chai, Yung-Lung Chen, Cheuk-Kwan Sun, Chih-Hung Chen, Gour-Shenq Kao, Sheung-Fat Ko, Hon-Kan Yip
This study tested the hypothesis that erythropoietin (EPO) and cyclosporine (CsA) could effectively reduce brain infarct area (BIA) in rat after acute ischemic stroke (AIS) through regulating inflammation, oxidative stress, MAPK family signaling and microRNA (miR-223/miR-30a/miR-383). Adult male Sprague-Dawley rats (n = 48) were equally divided into group 1 (sham control), group 2 (AIS), group 3 [AIS+EPO (5,000 IU/kg at 0.5/24/48 h, subcutaneous)] and group 4 [AIS+CsA (20.0 mg/kg at 0.5/24/48 h, intra-peritoneal)]...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28457030/evaluation-of-effect-of-vitamin-d-deficiency-on-anemia-and-erythropoietin-hyporesponsiveness-in-patients-of-chronic-kidney-disease
#2
N Nand, R Mittal
BACKGROUND: The role of vitamin D deficiency and inflammation levels in renal anemia has been documented. However, no study is available in India where the role of vitamin D supplementation in patients with hyporesponsiveness to increased doses of erythropoietin is available. Hence this study. MATERIAL AND METHODS: This study was conducted on 50 adult patients of CKD, on regular, twice weekly hemodialysis. It included 38 cases in group A with deficient serum vitamin D levels (<30 ng/ml) and 12 cases in group B with sufficient vitamin D levels (>30 ng/ml)...
February 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/28344481/stability-of-erythropoietin-repackaging-in-polypropylene-syringes-for-clinical-use
#3
Angela Marsili, Giorgia Puorro, Chiara Pane, Anna de Rosa, Giovanni Defazio, Carlo Casali, Antonio Cittadini, Giuseppe de Michele, Brunello Ettore Florio, Alessandro Filla, Francesco Saccà
Introduction: Epoetin alfa (Eprex®) is a subcutaneous, injectable formulation of short half-life recombinant human erythropoietin (rHuEPO). To current knowledge there are no published studies regarding the stability of rHuEPO once repackaging occurs (r-EPO) for clinical trial purposes. Materials and methods: We assessed EPO concentration in Eprex® and r-EPO syringes at 0, 60, 90, and 120 days after repackaging in polypropylene syringes. R-EPO was administered to 56 patients taking part in a clinical trial in Friedreich Ataxia...
February 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28288167/erythropoietin-epo-ameliorates-obesity-and-glucose-homeostasis-by-promoting-thermogenesis-and-endocrine-function-of-classical-brown-adipose-tissue-bat-in-diet-induced-obese-mice
#4
Kazuki Kodo, Satoru Sugimoto, Hisakazu Nakajima, Jun Mori, Ikuyo Itoh, Shota Fukuhara, Keiichi Shigehara, Taichiro Nishikawa, Kitaro Kosaka, Hajime Hosoi
Erythropoietin (EPO), clinically used as a hematopoietic drug, has received much attention due to its nonhematopoietic effects. EPO reportedly has beneficial effects on obesity and diabetes mellitus. We investigated whether interscapular brown adipose tissue (iBAT: main part of classical BAT) could play a role in EPO's anti-obesity and anti-diabetic effects in diet-induced obese mice. Four-week-old male C57BL/6J mice were fed a high-fat diet (HFD-Con), and half were additionally given an intraperitoneal injection of recombinant human EPO (200 IU/kg) (HFD-EPO) thrice a week for four weeks...
2017: PloS One
https://www.readbyqxmd.com/read/28168414/the-anti-aging-effect-of-erythropoietin-via-the-erk-nrf2-are-pathway-in-aging-rats
#5
Haiqin Wu, Jiaxin Zhao, Mengyi Chen, Huqing Wang, Qingling Yao, Jiaxin Fan, Meng Zhang
Erythropoietin (EPO) has a neuroprotective effect and can resist aging, which most likely occur through EPO increasing the activity of antioxidant enzymes and scavenging free radicals. In this study, we verified the anti-aging function of EPO and discussed the mechanism occurring through the extracellular signal-regulated kinase (ERK)/NF-E2-related factor 2 (Nrf2)-ARE pathway. A rat model of aging was induced by the continuous subcutaneous injection of 5 % D-galactose for 6 weeks. At the beginning of the sixth week, physiological saline or EPO was administered twice per day through a lateral ventricle system for a total of 7 days...
February 6, 2017: Journal of Molecular Neuroscience: MN
https://www.readbyqxmd.com/read/28054454/epoetin-beta-pegol-ameliorates-flow-mediated-dilation-with-improving-endothelial-nitric-oxide-synthase-coupling-state-in-nonobese-diabetic-rats
#6
Kenichi Serizawa, Kenji Yogo, Yoshihito Tashiro, Ryohei Kawasaki, Koichi Endo, Yasushi Shimonaka, Michinori Hirata
BACKGROUND/AIMS: Patients with diabetic nephropathy have a high cardiovascular mortality. Epoetin beta pegol (continuous erythropoietin receptor activator, C.E.R.A.) is a drug for the treatment of renal anemia. In this study, we investigated the effect of C.E.R.A. on vascular endothelial function as evaluated by flow-mediated dilation (FMD) and the relationship between hematopoiesis and FMD in diabetic nephropathy rats. METHODS: Male Spontaneously Diabetic Torii rats (SDT, 22 weeks old) were used...
April 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28039503/does-postoperative-erythropoietin-reduce-transfusions-and-hemodynamic-instability-following-liposuction-either-alone-or-associated-with-abdominoplasty-or-mammaplasty-a-comparative-prospective-study-of-50-consecutive-patients
#7
Rodrigo G Rosique, Marina J F Rosique, Mariana Quintino Rabelo
INTRODUCTION: Erythropoietin (EPO) is a hematopoietic growth factor and an alternative to avoid blood transfusion in high-blood-loss surgeries. We evaluate EPO efficacy to reduce clinically relevant anemia and dehydration in patients undergoing liposuction. METHODS: We prospectively evaluated 50 consecutive patients subjected to liposuction greater than 2.5 L and alternately assigned into two comparable groups (25 patients each), except for the postoperative administration of erythropoietin (4000 UI per day subcutaneously) during five consecutive days...
December 30, 2016: Aesthetic Plastic Surgery
https://www.readbyqxmd.com/read/27990008/anemia-treatment-by-erythropoiesis-stimulating-agents-during-the-6-months-before-initiation-of-hemodialysis-comparison-between-darbepoetin-alfa-and-continuous-erythropoietin-receptor-activator
#8
Tadashi Yoshida, Matsuhiko Hayashi
Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis-stimulating agents (ESA). Although results of previous studies showed that the hemoglobin level could not be maintained at initiation of dialysis in CKD patients treated with recombinant human erythropoietin, it remains undetermined if long-acting ESA are effective to prevent the progression of anemia at initiation of dialysis. In the present study, hemoglobin levels in 40 CKD patients treated with darbepoetin alfa (DA) and 15 CKD patients treated with a continuous erythropoietin receptor activator (CERA) were retrospectively compared during the 6 months period prior to initiation of dialysis...
December 19, 2016: Keio Journal of Medicine
https://www.readbyqxmd.com/read/27932518/epoetin-%C3%AE-induced-pure-red-cell-aplasia-an-unintended-consequence
#9
Muhammad Masoom Javaid, Priyanka Khatri, Srinivas Subramanian
Pure red cell aplasia is a rare condition associated with the use of recombinant human erythropoietin preparations. It has predominantly been associated with the subcutaneous use of a particular epoetin-α product, Eprex, and is rarely associated with intravenous use or with other commercially available products. Only a few cases of pure red cell aplasia secondary to epoetin-β have been reported. On account of its rarity, the condition can often be missed on initial presentation, leading to unnecessary investigations and delayed diagnosis...
March 2017: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/27640183/erythropoietin-does-not-activate-erythropoietin-receptor-signaling-or-lipolytic-pathways-in-human-subcutaneous-white-adipose-tissue-in-vivo
#10
Britt Christensen, Birgitte Nellemann, Jens Otto L Jørgensen, Steen B Pedersen, Niels Jessen
BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented. We therefore investigated the effects of acute and prolonged Epo exposure on human WAT in vivo. METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha...
September 17, 2016: Lipids in Health and Disease
https://www.readbyqxmd.com/read/27611985/recombinant-human-erythropoietin-improves-functional-recovery-in-patients-with-severe-traumatic-brain-injury-a-randomized-double-blind-and-controlled-clinical-trial
#11
RANDOMIZED CONTROLLED TRIAL
Zhong-Min Li, Yi-Lei Xiao, Jian-Xin Zhu, Feng-Yang Geng, Chuan-Jun Guo, Zong-Lei Chong, Le-Xin Wang
OBJECTIVE: To investigate the short-term effect of recombinant human erythropoietin (EPO) on patients with severe traumatic brain injury. METHODS: One hundred and fifty-nine patients with severe traumatic brain injury were randomly divided into EPO (n=79) and control group (n=80). EPO group was treated with subcutaneous injection of EPO (100 units/kg) on day 1, 3, 6, 9 and 12 following the brain injury. Glasgow outcome scores (GOS) were used to evaluate the outcomes three months after the treatment...
November 2016: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/27566219/efficacy-and-safety-of-adjuvant-recombinant-human-erythropoietin-and-ferrous-sulfate-as-treatment-for-iron-deficiency-anemia-during-the-third-trimester-of-pregnancy
#12
RANDOMIZED CONTROLLED TRIAL
Luis Rodrigo Sanchez-Gonzalez, Simón Enrique Castro-Melendez, Alejandra Cristina Angeles-Torres, Nohemi Castro-Cortina, Alfredo Escobar-Valencia, Alejandro Quiroga-Garza
PURPOSE: Gestational anemia increases the incidence of maternal and fetal complications. Adjuvant recombinant human erythropoietin (rHuEPO) has been used in patients who refuse blood transfusions, have a low response to treatment with iron sulfate, have limited time before birth, or have other illnesses that complicate the anemia. We demonstrated that the use of adjuvant rHuEPO with iron sulfate reduces the anemia time period and is innocuous to the fetus. METHOD: An experimental longitudinal prospective study; 100 pregnant women in their third trimester were included...
October 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27478604/pure-red-cell-aplasia-induced-by-epoetin-zeta
#13
Vincenzo Panichi, Guido Ricchiuti, Alessia Scatena, Lucia Del Vecchio, Francesco Locatelli
Pure red cell aplasia (PRCA) may develop in patients with chronic kidney disease receiving erythropoiesis-stimulating agents (ESA). We report on a 72-year-old patient who developed hypo-proliferative anaemia unresponsive to ESA following the administration of epoetin zeta subcutaneously for 7 months. On the basis of severe isolated hypoplasia of the erythroid line in the bone marrow and high-titre neutralizing anti-erythropoietin antibodies (Ab), a diagnosis of Ab-mediated PRCA was made. Epoetin zeta was discontinued and the patient was given steroids...
August 2016: Clinical Kidney Journal
https://www.readbyqxmd.com/read/27473384/pharmacokinetic-and-pharmacodynamic-equivalence-of-epoetin-hospira-and-epogen-after-single-subcutaneous-doses-to-healthy-male-subjects
#14
Dennis Stalker, Susan Reid, Atulkumar Ramaiya, Wayne A Wisemandle, Nancy E Martin
PURPOSE: The purpose of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of single 100 U/kg subcutaneous doses of Epoetin Hospira and Epogen in healthy male subjects as part of an overall program to demonstrate biosimilarity of Epoetin Hospira to the reference product Epogen. METHODS: This single-center, open-label, randomized, 2-period, crossover study was conducted in 81 healthy male subjects. Subjects were randomized to Sequence 1, in which they received 100 U/kg of Epoetin Hospira or to sequence 2, in which they received 100 U/kg Epogen subcutaneously in the first study period and the alternative treatment in the second study period...
August 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27452792/oxidative-stress-induces-the-decline-of-brain-epo-expression-in-aging-rats
#15
Xu Li, Yubao Chen, Siying Shao, Qing Tang, Weihai Chen, Yi Chen, Xiaoyu Xu
Brain Erythropoietin (EPO), an important neurotrophic factor and neuroprotective factor, was found to be associated with aging. Studies found EPO expression was significantly decreased in the hippocampus of aging rat compared with that of the youth. But mechanisms of the decline of the brain EPO during aging remain unclear. The present study utilized a d-galactose (d-gal)-induced aging model in which the inducement of aging was mainly oxidative injury, to explore underlying mechanisms for the decline of brain EPO in aging rats...
October 2016: Experimental Gerontology
https://www.readbyqxmd.com/read/27441542/clinical-application-of-recombinant-erythropoietin-in-beta-thalassaemia-intermedia
#16
Ch Asadov, Z Alimirzoyeva, M Hasanova, T Mammadova, A Shirinova
Research objective is to study the efficacy of recombinant erythropoietin (epoetin alfa) as alternative method of treatment beta-thalassemia intermedia. Study involved 58 patients with beta-thalassemia intermedia (23 women and 35 men). In all observed patients was defined levels of hemoglobin (Hb), red blood cells (RBC), erythrocyte indexes (MCV, MCH, MCHC), hemoglobin fractions (HbA, HbA2, HbF), serum ferritin, serum erythropoietin before and after administrated rEPO. All patients received rEPO during 6 month at the dose - 10000 IU subcutaneously...
June 2016: Georgian Medical News
https://www.readbyqxmd.com/read/27348783/increased-bone-formation-in-a-rabbit-long-bone-defect-model-after-single-local-and-single-systemic-application-of-erythropoietin
#17
Georg W Omlor, Kerstin Kleinschmidt, Simone Gantz, Anja Speicher, Thorsten Guehring, Wiltrud Richter
Background and purpose - Delayed bone healing with non-union is a common problem. Further options to increase bone healing together with surgery are needed. We therefore evaluated a 1-dose single application of erythropoietin (EPO), applied either locally to the defect or systemically during surgery, in a critical-size rabbit long-bone defect. Material and methods - 19 New Zealand White rabbits received a 15-mm defect in the radius diaphysis. An absorbable gelatin sponge was soaked with saline (control group and systemic treatment group) or EPO (local treatment group) and implanted into the gap...
August 2016: Acta Orthopaedica
https://www.readbyqxmd.com/read/27348021/a-cluster-of-epoetin-associated-pure-red-cell-aplasia-clinical-features-and-the-possible-association-of-hla-drb1-12-02
#18
Chuen Wen Tan, Wei-Chuen Tan-Koi, Jennifer Ng, Choong Meng Chan, William Ying Khee Hwang
Antibody-mediated pure red cell aplasia is a rare but serious complication in chronic kidney disease patients receiving recombinant human erythropoietin (r-HuEpo). Between April 2012 and May 2013, eight such cases were reported in our institution. Their clinical features were reviewed and their HLA alleles were compared with those of healthy controls. All patients were exposed to epoetin alfa (Eprex(®)) with polysorbate-80 as stabilizer via subcutaneous route with a mean age of 61.9 years and mean exposure of 11...
June 27, 2016: Pharmacogenomics
https://www.readbyqxmd.com/read/27344167/local-and-systemic-renin-angiotensin-system-participates-in-cardiopulmonary-renal-interactions-in-monocrotaline-induced-pulmonary-hypertension-in-the-rat
#19
Eva Malikova, Kristina Galkova, Peter Vavrinec, Diana Vavrincova-Yaghi, Zuzana Kmecova, Peter Krenek, Jan Klimas
Renin-angiotensin system (RAS) is one of the pathophysiological mechanisms in heart failure. Recently, involvement of the kidney in the disease progression has been proposed in patients with pulmonary arterial hypertension (PAH). We hypothesized that local and systemic RAS could be the central regulators of cardiopulmonary-renal interactions in experimental monocrotaline-induced pulmonary hypertension (PH) in rats. Male 12-week-old Wistar rats were injected subcutaneously with monocrotaline (60 mg/kg). The experiment was terminated 4 weeks after monocrotaline administration...
July 2016: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/27238922/administer-but-do-not-dispense-effect-of-change-in-medication-handling-by-nurses-on-outcomes-of-home-dialysis-patients
#20
Michael E Ullian, Cynthia A Martin, David M Ullian
BACKGROUND: To come into compliance with South Carolina statute, we changed how nurses handle medications (antibiotics, erythropoietin [EPO], calcitriol and heparin) in our outpatient home dialysis clinic. Nurses continued to administer medications in the clinic but no longer dispensed medications for patients to take home; instead, medications were dispensed from pharmacies to the patients by mail. We hypothesized that the abovementioned change in medication handling worsened clinical outcomes...
June 2016: American Journal of the Medical Sciences
keyword
keyword
21174
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"